SCHEMBL3485581

SCHEMBL3485581

O=C(Nc1cc(C(F)(F)F)ccc1Br)c1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRPK1 Q96SB4 2/20 0.60
KDR P35968 1/20 0.60
SRPK2 P78362 1/20 0.60
SRPK3 Q9UPE1 1/20 0.60
RXFP1 Q9HBX9 1/20 0.56
BRAF P15056 1/20 0.54
MAPT P10636 1/20 0.53
XBP1 P17861 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TRPA1 O75762 1/20 0.50
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023922 0.84 KCNMA1 (0.65) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL14453579 0.81 BRAF (0.65) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL1027433 0.81 KDR (0.58) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL14453684 0.80 PTGS1 (0.61) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL3921082 0.80 MAPT (0.58) RXFP1MAPTXBP1NPSR1RAB9A
SCHEMBL1703717 0.79 TAS2R14 (0.58) MAPTXBP1NPSR1CYP1A2CYP2C9
SCHEMBL12955313 0.78 BRAF (0.58) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL1026009 0.78 KDR (0.55) SRPK1KDRSRPK2SRPK3RXFP1
SCHEMBL7254538 0.77 CYP1A2 (0.58) RXFP1MAPTXBP1NPSR1CYP1A2
SCHEMBL4568244 0.77 TAS2R14 (0.54) MAPTXBP1NPSR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B9 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2019-05-22 EP disclosed
EP-2666481-B1 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA MASATOSHI (JP) 2018-11-14 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
EP-1712242-B1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA MASATOSHI (JP) 2018-05-30 EP disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
US-8816089-B2 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Hagiwara, Masatoshi (JP) 2014-08-26 US disclosed
CN-101837125-B Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient HAGIWARA MASATOSHI 2014-02-26 CN disclosed
EP-2666481-A2 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient HAGIWARA, Masatoshi (JP) 2013-11-27 EP disclosed
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY MASATOSHI HAGIWARA 2010-01-21 US disclosed
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY MASATOSHI HAGIWARA 2010-01-21 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-7569536-B2 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene Hagiwara, Masatoshi (JP) 2009-08-04 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene HAGIWARA, MASATOSHI (JP) 2007-06-14 US disclosed
CN-1921885-A Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient HAGIWARA MASATOSHI (JP) 2007-02-28 CN disclosed
EP-1712242-A1 METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT HAGIWARA, Masatoshi (JP) 2006-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135367-A1 Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene SRPK1, SARS1, SRPK3 SRPK1 1/4885KDR 2410/4885SRPK2 4/4885
US-20100016359-A1 METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY SRPK1, SRPK3, SRPK2 SRPK1 1/4885KDR 4350/4885SRPK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.